TOKYO, Sept 12, 2017 - (ACN Newswire) - Eisai Co., Ltd. announced today that it has been selected for a fifth consecutive year of membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).
The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 as the first global SRI indices in the world and assesses the corporate sustainability performance of eligible member companies based on economic, environmental and social criteria. This year, the DJSI Asia Pacific has selected 152 companies leading the way in sustainability (72 of which are from Japan) from among the region's top 614 companies. Eisai received high scores particularly in categories such as Codes of Business Conduct, Product Quality and Recall Management, Labor Practice Indicators as well as Strategy to Improve Access to Drugs or Products.
In addition to the DJSI Asia Pacific, Eisai has been selected for the 16th consecutive year since 2002 as a member of the FTSE4Good Index Series, another global benchmark SRI index.
The Eisai Group's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Guided by this philosophy, Eisai will continue to develop innovative new drugs and make them available to patients around the world as early as possible to fulfill its social responsibility and secure the trust of stakeholders.
About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Source: Eisai
Contact:
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2017 JCN Newswire . All rights reserved.
